Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director · Chief Executive Officer | August 19, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 19, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,485 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Gift · Disposed 528 · Balance 35,485 |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 43,803 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 43,803 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 82 | $144.71 | $11,866.22 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 4 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,361 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 34 | $144.70 | $4,919.63 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,443 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 79 | $144.68 | $11,429.72 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,477 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 84 | $144.67 | $12,152.28 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,556 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 169 | $144.66 | $24,447.54 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 30 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,640 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5 | $144.66 | $723.28 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 29 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,809 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1 | $144.65 | $144.65 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 28 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,814 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 6 | $144.63 | $867.78 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 27 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,815 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 10 | $144.63 | $1,446.25 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 26 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,821 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 87 | $144.61 | $12,581.07 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 25 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,831 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $144.61 | $14,460.50 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 24 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,918 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 81 | $144.59 | $11,711.79 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 23 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,018 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 11 | $144.58 | $1,590.38 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 22 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,099 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 16 | $144.57 | $2,313.12 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 21 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,110 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 105 | $144.54 | $15,176.70 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 20 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,126 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 201 | $144.47 | $29,038.47 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 19 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,231 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $144.44 | $14,444.00 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 18 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,432 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $144.42 | $14,442.00 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 17 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,532 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 84 | $144.33 | $12,123.72 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 16 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,632 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 81 | $144.32 | $11,689.92 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 15 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,716 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 92 | $144.15 | $13,261.80 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 14 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,797 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 91 | $144.13 | $13,115.38 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 13 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,889 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 92 | $144.11 | $13,258.12 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 12 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,980 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 138 | $144.04 | $19,876.83 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 11 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,072 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 82 | $143.96 | $11,804.72 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 10 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,210 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 68 | $143.95 | $9,788.60 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 9 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,292 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 94 | $143.94 | $13,529.89 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 8 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,360 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 78 | $143.93 | $11,226.54 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 7 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,454 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 69 | $143.91 | $9,929.45 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 6 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,532 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 82 | $143.90 | $11,799.39 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 5 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,601 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 95 | $143.86 | $13,666.23 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 4 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,683 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 99 | $143.79 | $14,235.21 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,778 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 96 | $143.73 | $13,798.08 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,877 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 87 | $143.70 | $12,501.90 |
DisclosureSEC source: 0001127602-19-034699 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,973 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $137.32 | $13,731.50 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 12 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,060 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 206 | $137.29 | $28,281.74 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 11 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,160 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 240 | $137.29 | $32,948.40 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 10 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,366 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5 | $137.28 | $686.40 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 9 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,606 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 55 | $137.25 | $7,548.75 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 8 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,611 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $137.24 | $13,724.00 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 7 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,666 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 216 | $137.23 | $29,641.68 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 6 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,766 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $137.19 | $27,437.00 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 5 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,982 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 90 | $137.18 | $12,346.20 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 4 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,182 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 159 | $137.17 | $21,810.03 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,272 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 28 | $137.17 | $3,840.62 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,431 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $137.16 | $13,715.50 |
DisclosureSEC source: 0001127602-19-032771 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,459 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,204 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · derivative · entry 34 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,614 Underlying: Common Stock · 3,204 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,492 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · derivative · entry 33 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,985 Underlying: Common Stock · 3,492 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,675 | $0.00 Strike: $73.70 | $0.00 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · derivative · entry 32 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,675 Underlying: Common Stock · 1,675 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,233 | $0.00 Strike: $76.67 | $0.00 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · derivative · entry 31 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,233 shares Expires 2020-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.